Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine-Reference-Cited by-同舟云学术

Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine

Published:2022-07-15 Issue:4 Volume:43 Page:505-511
ISSN:1868-1883
Container-title:Hormone Molecular Biology and Clinical Investigation
language:en
Short-container-title:

Author:

Shoib Sheikh¹,Kotra Madhulika²,Javed Sana³,Nguyen Vinh-Son⁴,Malathesh Barikar C.⁵^ORCID

Affiliation:

1. Department of Psychiatry , Jawahar Lal Nehru Memorial Hospital , Srinagar , Kashmir , India

2. M S Ramaiah Medical College , Bangalore , India

3. Faculty of Medicine, Aleppo University , Aleppo , Syria

4. Department of Psychiatry and Behavioral Sciences , Baylor College of Medicine , Houston , TX , USA

5. Department of Psychiatry , AIIMS – Bibinagar , Hyderabad , Telangana , India

Abstract

Abstract Esketamine, which is an S-enantiomer of ketamine, is better than conventional antidepressants and even better than R-ketamine. This article discusses the mechanism of action of Esketamine, how different it is from other antidepressants, its side effect profile, indications for use, various routes of administration and the review of existing literature on Esketamine.

Publisher

Walter de Gruyter GmbH

Subject

Endocrinology,Molecular Biology,General Medicine,Endocrinology, Diabetes and Metabolism

Link

https://www.degruyter.com/document/doi/10.1515/hmbci-2021-0099/pdf

Reference33 articles.

1. Bahr, R, Lopez, A, Rey, JA. Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. P T 2019;44:340–75.

2. Murrough, JW. Ketamine for depression: an update. Biol Psychiatr 2016;80:416–8. https://doi.org/10.1016/j.biopsych.2016.07.005.

3. Molero, P, Ramos-Quiroga, JA, Martin-Santos, R, Calvo-Sánchez, E, Gutiérrez-Rojas, L, Meana, JJ. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs 2018;32:411–20. https://doi.org/10.1007/s40263-018-0519-3.

4. Turner, EH. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatr 2019;6:977–9. https://doi.org/10.1016/s2215-0366(19)30394-3.

5. Salahudeen, MS, Wright, CM, Peterson, GM. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Ther Adv Drug Saf 2020;11:2042098620937899. https://doi.org/10.1177/2042098620937899.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of esketamine and remifentanil in combination with propofol in patients with septic shock receiving invasive mechanical ventilation: a randomized controlled trial;2024-03-21

2. Efficacy and safety of perioperative application of esketamine on postpartum depression: A meta-analysis of randomized controlled studies;Psychiatry Research;2024-03

3. Esketamine combined with sufentanil versus sufentanil in patient-controlled intravenous analgesia: a meta-analysis;Frontiers in Pharmacology;2024-02-07

4. Effect of intravenous induction with different doses of Esketamine combined with propofol and sufentanil on intraocular pressure among pediatric strabismus surgery: a randomized clinical trial;BMC Anesthesiology;2023-08-15